Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Sodium Cridanimod Plus Progestin in Progesterone Receptor–Negative Recurrent or Persistent Endometrial Carcinoma
2014-001434-29Phase 2Completed
- Sponsor
- AS Kevelt
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cridanimod in endometrial cancer (EC) and endometrioid adenocarcinoma, sponsored by AS Kevelt. Primary endpoint: Objective response rate. Started Jul 2014; status: completed.
02
Drugs
cridanimod
03
Conditions
endometrial cancer (EC)endometrioid adenocarcinoma
Beyond the preview
Go deeper on 2014-001434-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001434-29.